Google+ Badge

Sunday, June 7, 2015

Cancer Research: Immune system marker for therapy-resistant prostate cancer ♦ Benefit of surgery for ductal carcinoma in-situ ♦ Immune system marker for therapy-resistant prostate cancer

Immune system marker for therapy-resistant prostate cancer A research team shows how signaling by an immune system component called interleukin-6 (IL-6) appears to play an important role in driving aggressive.
Cancer screening increase may reflect Affordable Care Act provision Screening for colorectal cancer increased in lower socioeconomic status individuals after 2008, perhaps reflecting the Affordable Care Act's removal of financial barriers to screening.
Cancer overtakes cardiovascular disease as UK's number one killer, but only among men Cancer has overtaken cardiovascular disease, which includes heart disease and stroke, as the UK's number one killer -- but only among men, reveals research. Cardiovascular disease is still the most common cause of death among women, and kills more young women than breast cancer.
Benefit of surgery for ductal carcinoma in-situ investigated Breast surgery performed at or shortly after a diagnosis of low-grade ductal carcinoma in-situ (DCIS) did not significantly change patients' survival rate. The team finds that the survival rate for those with intermediate- and high-grade DCIS does improve with surgery, but the work raises concerns about over treatment and the necessity and benefit of surgery for all patients with low-grade DCIS.

No comments:

Post a Comment